BPC 157 has been shown in rat studies to improve healing of GI fistulas by accelerating the rate of repair and leading to more frequent closure of the fistula
If youre not already subscribed, join 69,000+ people who receive actionable insights directly in their inbox each week
BPC-157 Mechanism Growth factor upregulation increases expression of VEGF, FGF, and other growth factors at injury sites Angiogenesis promotes formation of new blood vessels, improving nutrient and oxygen delivery to damaged tissue Nitric oxide modulation regulates blood flow and inflammation through the NO system Gut-brain axis derived from gastric juice, with particular affinity for GI tissue repair TB-500 Mechanism Actin upregulation increases production of actin, a key protein for cell structure, migration, and repair Cell migration promotes movement of repair cells (fibroblasts, endothelial cells) to the injury site Anti-inflammatory reduces inflammatory cytokines and dampens excessive immune response Systemic reach low molecular weight allows it to travel through tissues more easily than most peptides Combined Effect Multi-pathway repair addresses both the infrastructure (blood supply, growth factors) and the workforce (cell migration, tissue building) Broader tissue coverage BPC-157's gut and tendon affinity pairs with TB-500's muscle and joint effects Faster onset simultaneous action on different repair bottlenecks may accelerate overall healing timeline Reduced inflammation both peptides modulate inflammation through different pathways This isn't theoretical stacking the mechanisms are genuinely complementary
Risks and Considerations Potential Side Effects Potential Side Effects While peptides offer significant benefits, they should be used responsibly and under medical supervision
Lipotropic Injections Procedure All medications are not suitable for everybody
The total human evidence base, as of this writing, consists of the following: 1) a Phase I safety trial of 42 healthy volunteers that was registered in 2015, canceled in 2016, and never published, 2) a retrospective case series of 12 patients with knee pain, no control group, and no validated outcome measure, and 3) a 2025 pilot safety study involving two healthy adults who received intravenous infusions at a single private clinic in Florida
